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Summary 
 
Mastitis is considered the most costly disease 
in the U.S. dairy industry. Treatment of clini-
cal mastitis is the major reason for antibiotic 
contamination of products on U.S. dairy 
farms. A survey of 183 dairy producers was 
conducted to determine their perceptions re-
garding clinical mastitis treatments and what 
constituted their treatment regimens. Results 
indicated that 33% of dairy producers used a 
coliform vaccine, 10% used a Staphylococcus 
aureus vaccine, and 38% did no prestripping 
before milking cows. Obtaining a clinical cure 
(restoration of normal milk) was considered 
the most important aspect of mastitis treat-
ment success (110/183; 60%) compared to 
bacteriological cure (absence of bacterial 
pathogen), somatic cell count cure (cells count 
back to near normal concentrations), milk 
production (back to near pre-mastitis levels), 
and udder firmness (back to near normal firm-
ness). Average treatment success for mastitis 
reported by the 183 producers was 70%, with 
a range of 10 to 100%. Seventy-three (92%) 
producers listed “off-feed” as a good measure 
of the severity of clinical mastitis, followed 
closely by general appearance (91%). Appear-
ance of udder and milk, droopy ears, appear-
ance of the eyes, and low milk production 
were other popular methods used to determine 
the severity of clinical mastitis. Dairy produc-
ers believed that 5.3 days (range of 1 to 45 
days) passed between first recognition of a  
clinical case until normal milk was restored. 
Only 34% of producers utilized rectal tem-
peratures as a diagnostic tool for mastitis. 
Many treatments used were extra-label and 
some were potentially illegal. However, the 
results presented demonstrate a wide diversity 
of products used and a general lack of consen-
sus of what is considered efficacious mastitis 
treatment. In addition, drug dosages and dura-
tion of therapy varied considerably. Greater 
education on proper dosages, durations, and 
potential efficacy of treatments should be 
beneficial. A clear need exists for conducting 
efficacy studies to help establish necessary 
and justified treatments for clinical mastitis. 
 
(Key Words: Milking Routines, Mastitis Sur-
vey, Mastitis Therapies) 
 
Introduction 
 
 Although mastitis is considered the most 
costly disease in the U.S. dairy industry and 
treatment is the major reason for antibiotic 
contamination of dairy products, few pub-
lished, peer-reviewed studies that document 
effective antibiotic therapies are available. 
Despite the lack of efficacy data, dairy pro-
ducers and veterinarians desire to treat cases 
of clinical mastitis, sometimes with extra-label 
or illegal antibiotic therapies. A prior message 
on  American Association of Bovine  Prac-
titioners (AABP-L) reported the use of 
gentamicin, enrofloxacin, and florfenicol for  
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treatment of clinical mastitis; tilmicosin and 
florfenicol were administered to cows entering 
the non-lactating period (March 1997). None 
of the aforementioned antibiotics is approved 
for use in lactating dairy cows, and use of en-
rofloxacin is illegal. This extra-label use of 
antibiotics for clinical mastitis illustrates the 
frustration and lack of faith dairy producers 
and veterinarians have with approved mastitis 
treatment products. Research documenting the 
most effective methods of treating clinical 
mastitis would benefit producers, veterinari-
ans, and consumers by determining economi-
cal treatments and decreasing the risk of anti-
biotic residues in consumer milk products. 
 
 In the early 1990s, two intramammary an-
tibiotic preparations were compared to oxyto-
cin for treatment of mild clinical mastitis in 
three California dairies. No significant differ-
ences in clinical or bacteriological cures were 
reported among the 254 cases studied. Most 
mastitis researchers generally agree that anti-
biotic therapy with approved intramammary 
preparations for mastitis caused by gram-
negative pathogens is of little value. Further, 
antibiotic therapy against gram-positive or-
ganisms also may be ineffective to produce 
clinical recovery. Anti-inflammatory therapy 
has not been shown to alter recovery rates. 
 
 Few controlled studies have been pub-
lished regarding efficacy of non-antibiotic 
mastitis therapies. Frequent milk-out (FMO), a 
common therapy for clinical mastitis, was 
found to be ineffective when compared to 
nontreated controls. Fluid therapy (intrave-
nous, oral, and hypertonic) is considered vital 
for cases of acute clinical mastitis, yet little 
research has been performed. Calcium therapy 
has been recommended for gram-negative 
mastitis. Little applied and practical research 
has been conducted to aid the producer and 
veterinarian in treating or managing mastitis.  
 
 The primary objective of this observa-
tional study was to document dairy producer 
perceptions about clinical mastitis treatment 
and what constituted their treatment regimens. 
A questionnaire was administered regarding 
treatment methods and the expected outcomes. 
 
Experimental Procedures 
 
 A list of Kansas dairy herds was obtained 
from the 2001 Kansas Dairy Producer Direc-
tory. An effort was made to administer the 
questionnaire to 25% of dairy producers 
within any given county. Dairy producers 
were contacted by telephone, the project was 
described, and producers were asked if they 
would be willing to participate. If agreeable, a 
time was set to administer the questionnaire. 
The questionnaire was administered in person 
by the author. 
 
Results and Discussion 
 
 One hundred eighty-three dairy producers 
were surveyed. Only two were not available at 
the time of appointment. The first question-
naire was administered in December 2001 and 
the last was August 2003. The rolling herd 
average for milk, according to producer esti-
mates, was 18,733 lb, with a range of 3,660 to 
28,000. The average estimated rolling herd 
somatic cell count (SCC) was 318,000 
cells/mL, with a range of 75,000 to 729,000. 
Twenty-one herds (11.5%) milk at least a por-
tion of their cows more than twice daily. Av-
erage number of cows (both lactating and dry) 
per herd was 345, with a range of 9 to 7,000. 
 
 Thirty-three percent of producers use a 
coliform vaccine, but only 10% of producers 
use a Staphylococcus aureus vaccine. Two 
producers reported using an autogenous strep-
tococcus vaccine. 
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 Thirty-eight percent of producers reported 
that pre-stripping was not a routine milking 
procedure in their herds, suggesting that mild 
cases of clinical mastitis would not be identi-
fied. Twelve percent reported forestripping 
some of the time, whereas the remaining 50% 
routinely performed forestripping. Among 
those using forestripping, only 7 of 91 (7.6%) 
strip the milk on objects other than the parlor 
floor or gutter. Only three reported using a 
strip cup. 
 
 Producers were asked to rank clinical cure 
(normal milk), bacteriological cure (absence 
of bacterial pathogen), SCC cure (cell count 
back to near normal levels), milk production 
(back to near pre-mastitis levels), and udder 
firmness (back to near normal firmness) in 
order of importance to mastitis treatment suc-
cess. Obtaining a clinical cure was considered 
the most important aspect of treatment success 
(110/183). Thirty-four producers considered 
getting the udder back to normal firmness 
most important, 17 (9.3%) considered lower-
ing the SCC most important, 12 (6.6%) con-
sidered a bacteriologic cure most important, 
and 10 (5.5%) considered milk production 
most important to evaluate treatment success. 
The factor considered least important was bac-
teriologic cure (71/183; 38.8%); whereas only 
8 (4.4%) producers considered clinical cure 
least important. The average treatment success 
reported by the 183 producers was 70% with a 
range of 10 to 100%. 
 
 Producers were asked how many days 
passed between recognition of the clinical 
case to normal milk. The average number of 
days was 5.3, with a range of 1 to 45. Like-
wise producers were asked the number of days 
until a bacteriologic cure. The average number 
of days was 10.7, with a range of immediate 
cure (2 producers) to never cured (12 produc-
ers).  Average days reported to near normal  
 
SCC, milk production, and udder were 16.8, 
9.8, and 10.2, respectively. 
 
 Seventy-nine producers were queried con-
cerning methods used to determine severity of 
clinical mastitis. Seventy-three (92%) produc-
ers listed “off-feed” as a good measure of se-
verity, followed closely by general appearance 
(91%). Appearance of udder and milk, droopy 
ears, appearance of the eyes, and low milk 
production were the other major methods used 
to determine the severity of clinical mastitis. 
Only 27 (34%) producers used rectal tempera-
tures, and the average critical rectal tempera-
ture was 102.8°F, with a range of 100 to 104. 
Other methods listed as aids to determine se-
verity were diarrhea, respiratory signs, kicking 
or touchy, entering the parlor out of order, de-
hydrated, slobbering, not cleaning nose, iso-
lated, and walking stiffly. 
 
 Five typical cases of clinical mastitis were 
described to dairy producers (chronic, mild, 
moderate, severe, and non-responding), and 
they were asked how each case would be 
managed. Only data on the chronic, mild, and 
moderate cases are reported herein. 
 
Chronic Mastitis 
 
 Chronic cases consisted of excellent milk-
ing cows that were 4 to 5 months pregnant 
displaying milk clots from a single quarter. 
These cows had episodes of clinical mastitis 
every 1 to 2 months, and each clinical phase 
lasted 1 to 2 weeks regardless of management 
or treatment. These cows were not clinically 
ill or had firm or hard udders. Thirty-eight 
percent of producers used antibiotics in an ex-
tra-label manner, with only 4.4% using antibi-
otics according to label directions. Eight per-
cent used no drugs, but would take extra care 
to strip out the clots, 4.4% used no treatment 
of any kind, 14% used only oxytocin for  
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chronic cases, and one producer removed teats 
from the offending quarter. 
  
 Intramammary treatment. Approximately 
31% of producers reported using intramam-
mary antibiotics to treat chronic cases. Of the 
56 herds that used a product intramammary, 
38% use a cephapirin product (Today® or 
Cefa-Lak®), 21% used pirlimycin (Pirsue®), 
and < 4% of producers used other labeled in-
tramammary antibiotics. One producer used a 
veterinarian-mixed product, one used vinegar, 
and one used a neomycin/dexamethasone mix-
ture. Five producers reported using two differ-
ent intramammary products in some combina-
tion on chronic mastitis. 
 SystemicTreatment-Antibiotics. Eighteen 
percent (33/183) of producers reported using 
systemic antibiotics to treat chronic cases. 
Eleven producers used penicillin either intra-
muscularly or subcutaneously on chronic 
cases, with daily dosages ranging from 20 to 
50 mL as a one-time treatment or until clots 
were resolved. Fifteen producers use a ceftio-
fur product (Naxcel® or Excenel®), most of-
ten following label directions. Other products 
listed were oxytetracycline, a custom, veteri-
narian-mixed product, and LS-50. 
 
 Systemic Treatment-Anti-Inflammatory. 
Four of the 183 producers reported using an 
anti-inflammatory drug for chronic mastitis 
cases. Products used were intramammary and 
external dimethyl sulfoxide (DMSO), aspirin 
(orally), dexamethasone intramammary, and a 
combination of dexamethasone and intramus-
cular injections of Banamine®. 
 
 Miscellaneous Treatments. Other prod-
ucts and procedures used included: vitamins 
A, B, D, and E, hyperimmune serums, whey 
products, Tramisol®, mint or oil products, hy-
drotherapy, and energy or stress boluses. 
 
 
 
Mild Clinical Mastitis 
 
 A mild case was indicated when a cow had 
clots in one quarter, but no evidence of sys-
temic illness or firmness of the affected quar-
ter. This would be the very first case of clini-
cal mastitis observed in the cow. Sixty-four 
percent of producers used antibiotics in an ex-
tra-label manner, whereas 13% reported using 
antibiotics according to label directions. One 
producer did not use any drugs, but would 
take extra care to strip out the clots, 11% used 
no treatment of any kind, and 8% use only 
oxytocin on mild cases. 
 
 Intramammary Treatment. Approxi-
mately 62% of producers used intramammary 
antibiotics to treat mild cases. Of the 113 pro-
ducers who used intramammary products, 
49% used a cephapirin product (Today® or 
Cefa-Lak®), 27% used pirlimycin (Pirsue®), 
about 7% used amoxicillin, 4% each used ei-
ther novobiocin/penicillin or cloxicillin, 3% 
used penicillin with or without a steroid, 2% 
used ampicillin, and one producer each used a 
homebrew, dry-cow antibiotic, gentamicin 
with dexamethasone, and neomycin with dex-
amethasone. Two producers used two differ-
ent intramammary products in sequence. 
 
 Systemic Treatment-Antibiotics. Thirty-
two percent (58/183) of producers reported 
using systemic antibiotics to treat mild cases. 
Twenty-five producers used ceftiofur (Nax-
cel® or Excenel®), 19 producers used penicil-
lin or a penicillin-like antibiotic, five used a 
tetracycline antibiotic, and six producers used  
a veterinarian mix, spectinomycin-lincomycin 
(LS-50), Micotil®, or Albon® (sulfadimeth-
oxine). 
 
 Systemic Treatment-Anti-Inflammatory. 
Only 3 of the 183 producers reported using an 
anti-inflammatory drug for mild cases. 
 
 34
 Miscellaneous Treatments. Sixty-five 
producers reported using various other prod-
ucts. Fifty-one producers used oxytocin once 
or for the rest of the lactation, mostly pre-
milking, at doses ranging from 0.5 to 5 mL. 
Four producers routinely used vitamins or nu-
tritional supplements. Four producers used a 
hyperimmune serum product. Two producers 
routinely used ointments, and one used a teat 
cannula. 
 
Moderate Clinical Mastitis 
 
 The moderate case was described as a cow 
with clots in one quarter that was slightly firm 
and warm. This cow had a temperature of 
104.5ºF, but was not off-feed or dehydrated. 
Clinical mastitis had not previously occurred 
in this quarter. 
  Fluid Therapy. Five percent of producers 
would administer some type of fluid therapy 
(hypertonic saline, dextrose, 3 to 5 gallons of 
water orally, or an oral drench mixture con-
sisting of beer, rumen fluid, water, and pro-
pylene glycol). 
 
 Intramammary Treatment. Seventy per-
cent of producers would use intramammary 
antibiotics and three producers relied on their 
veterinarians to treat the cow with moderate 
clinical mastitis. Of the 128 herds that used a 
product intramammary, 52% used a 
cephapirin product (Today® or Cefa-Lak®), 
20% used pirlimycin (Pirsue®), about 6% 
used amoxicillin, 4% used novobio-
cin/penicillin, and 2% used cloxicillin. Four 
producers used a single intramammary prod-
uct without a preference. Nine producers rou-
tinely used a combination of intramammary 
products (five used two intramammary labeled 
products either one after the other or at the 
same time; two used a veterinary mix and an 
approved intramammary product; one used 
spectinomycin and Today®, and one used a 
dry cow product followed by Pirsue®). Ten 
producers used other combinations or dry cow 
intramammary antibiotics (five used penicillin 
and a steroid; two used a dry-cow intramam-
mary antibiotic, one used penicillin-vitamin 
mix, one used a neomycin-dexamethasone 
mix, and one used a gentamicin-
dexamethasone mix). 
 
 Systemic Treatment-Antibiotics. Five 
producers relied on their veterinarian to treat 
their cows with moderate clinical mastitis. 
Sixty-three percent (112/178) of producers 
reported using systemic antibiotics to treat 
moderate cases. Producers reported using 
penicillin (23%), ceftiofur (19%), tetracycline 
products (9%), a combination of antibiotics 
(4%: penicillin and tetracycline, sulfa-
containing drugs or ceftiofur, erythromycin 
and tetracycline, ceftiofur and Albon®), am-
picillin (2%), vet mixes (2%), sulfa products 
(2%), LS-50 (<1%), Micotil® (<1%), and one 
producer had no preference. Dosages for peni-
cillin ranged from 10 to 75 ml. Dosages for 
ceftiofur ranged from 10 to 30 mL. Dosages 
for tetracycline products ranged from 20 to 
110 mL. 
 
 Systemic Treatment-Anti-Inflammatory. 
Nearly 75% of producers do not use anti-
inflammatory products to treat cows with 
moderate clinical mastitis. Banamine® was 
routinely used by 12% of producers, with 
doses ranging from 10 to 25 mL. A steroid 
was used by 8% of producers, with dosages 
ranging from 1 to 110 ml. Five producers used 
aspirin as their sole anti-inflammatory drug. 
Four producers used a combination of anti-
inflammatory drugs, and two producers had no 
specific preference. 
 
 Miscellaneous Treatments. Forty-two 
percent of producers (75/178) that treated their 
own moderate cases of clinical mastitis used 
other forms of treatment. Oxytocin was used 
by 60 producers, 12 used some form of mint 
oil externally, 10 used vitamins or nutritional 
supplements, five used hyperimmune serum, 
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one used DMSO, one used cold water hydro-
therapy, one used an antihistamine, and one 
used Tramisol®. 
 
Conclusions 
 
 The purpose of this study was to neither 
support nor condemn treatments for clinical 
mastitis used by Kansas dairy producers. 
Many of the treatments used are extra-label 
and some were potentially illegal. However, 
the results presented demonstrate a wide di-
versity of products used and a general lack of 
consensus of what is considered effective 
mastitis treatment. In addition, drug dosages 
and duration of therapy varied considerably. 
Greater education on proper dosages, dura-
tions, and potential efficacy of treatments 
should be beneficial. 
 Although the producers generally did not 
have a severity scoring scheme, the amount of 
treatment seemed to increase with increasing 
severity of mastitis. Producer-reported treat-
ment success rates were not different for those 
who used intramammary antibiotics compared 
to those who did not. A clear need exists to 
conduct efficacy studies to help establish nec-
essary and justified treatments producers can 
use for clinical mastitis. 
 
